Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05071183 | A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | Turning Point Therapeutics, Inc.INDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | terminated | Phase 1 | 29 | Pyramid BiosciencesINDUSTRY | 11 | Mar 28, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT04761601 | First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 32 | 1200 Pharma, LLCINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04430348 | PTX-35 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 22 | Pelican Therapeutics, Inc.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04144140 | Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | terminated | Phase 1 | 24 | Eisai Inc.INDUSTRY | 5 | Mar 7, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04158583 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 76 | Hoffmann-La RocheINDUSTRY | 5 | Mar 4, 2024 | clinicaltrials |
| NCT04920383 | ALPN-202 With PD-1 Inhibition in Advanced Malignancies(NEON-2) | terminated | Phase 1 | 29 | Alpine Immune Sciences, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04892043 | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 5 | SQZ BiotechnologiesINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05357898 | Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | SQZ BiotechnologiesINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03573544 | This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | terminated | Phase 1 / Phase 2 | 54 | OBI Pharma, IncINDUSTRY | 2 | Feb 22, 2024 | clinicaltrials |
| NCT00930332 | Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain | terminated | Phase 1 | 8 | NCIC Clinical Trials GroupNETWORK | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04842630 | A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors | terminated | Phase 1 | 11 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04675996 | First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 25 | InteRNAINDUSTRY | 2 | Feb 8, 2024 | clinicaltrials |
| NCT05430555 | A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors(IMAG1NE) | terminated | Phase 1 / Phase 2 | 23 | T-knife GmbHINDUSTRY | 5 | Feb 7, 2024 | clinicaltrials |
| NCT03209401 | Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies | terminated | Phase 1 | 23 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT01311713 | Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 45 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT04609579 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | terminated | Phase 1 | 27 | Stingthera, Inc.INDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04267939 | ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | terminated | Phase 1 | 14 | BayerINDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03928314 | Study of ORIC-101 in Combination With Anticancer Therapy | terminated | Phase 1 | 83 | ORIC PharmaceuticalsINDUSTRY | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04513067 | A Safety Study of YQ23 in Advanced Solid Tumors Patients | terminated | Phase 1 | 3 | New Beta Innovation LimitedINDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03225105 | M3541 in Combination With Radiotherapy in Solid Tumors | terminated | Phase 1 | 15 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03954704 | Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors | terminated | Phase 1 | 22 | Gilead SciencesINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05920408 | Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Exscientia AI LimitedINDUSTRY | 2 | Nov 8, 2023 | clinicaltrials |
| NCT05221385 | Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma | terminated | Phase 1 | 58 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04168320 | SBRT-based PArtial Tumor Irradiation of HYpoxic Segment(SBRT-PATHY) | terminated | Phase 1 | 30 | Klinikum Klagenfurt am WörtherseeOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05255484 | Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 24 | LaNova Medicines LimitedINDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03690154 | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | terminated | Phase 1 | 67 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 2 | Oct 13, 2023 | clinicaltrials |
| NCT05073484 | Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients | terminated | Phase 1 | 13 | Bio-Thera SolutionsINDUSTRY | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05120375 | Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China | terminated | Phase 1 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01047007 | A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005 | terminated | Phase 1 | 11 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT04551885 | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 12 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04865159 | Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 6 | Kura Oncology, Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05069935 | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 16 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05698888 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | terminated | Phase 1 | 2 | Virtuoso BINco, Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | terminated | Phase 1 | 8 | Biotheryx, Inc.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05470933 | A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors | terminated | Phase 1 | 7 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 1, 2023 | clinicaltrials |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | terminated | Phase 1 | 2 | AeRang KimOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03139370 | Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2024source: clinicaltrials